Micromedex® Compendia Resources
Through the process established by the Centers for Medicare and Medicaid Services (CMS), Micromedex® DRUGDEX® is recognized by CMS as a compendium for the determination of payment for medically-accepted off-label uses for anti-cancer regimens. Effective January 1, 2010, new requirements were implemented that include a provision for providing transparency of processes used to evaluate therapies and to identify potential conflicts of interest. Specifically, publishers of compendia must now make the following information available via their public websites:
- Criteria used to evaluate the request (therapy)
- Disclosure of evidence considered
- Meeting minutes and records of votes for disposition of the request (therapy)
- Names of individuals who have substantively participated in the development of the compendia recommendations and disclosure of any potential conflicts of interest
To meet these requirements, documents detailing this information for each drug/off-label use pair published on or after January 1, 2010 are posted below. Information is organized by drug name, with the document title indicating the off-label use. Further transparency regarding Micromedex Off-Label processes can be found in the Micromedex Compendia Uses Policy.